Andrin Oswald, MD
Chief Executive Officer
Andrin serves as CENTOGENE’s Chief Executive Officer.
He was most recently the Delegate for COVID-19 Vaccines and Immunotherapies for the Federal Government of Switzerland, ...
... helping develop response and procurement strategies while advising the Swiss government on key decisions.
Prior to that, Andrin was Director of Life Science Industry Engagement and Partnerships at the Bill & Melinda Gates Foundation, a role he held for four years in which he led the Foundation’s engagement with the industry and supported teams in developing and advancing its Global Health and Development priorities in R&D and delivery technologies. Prior to his role at the Bill & Melinda Gates Foundation, he oversaw business integration at GlaxoSmithKline, working directly with the CEO to advise on business and integration strategy. Before joining GlaxoSmithKline, he spent more than 10 years in a variety of leadership roles at Novartis, including serving as Assistant to the Chairman and CEO of Novartis International AG; Country President for Novartis South Korea; Head of Global Development Franchises and a member of the Executive Committee for Novartis Pharma; and ultimately, CEO/Division Head of Novartis Vaccines & Diagnostics and a member of the Novartis Executive Committee, based in Boston. Andrin began his career in 1999 with McKinsey & Company, where he worked in various roles managing relationships and supporting projects with leading pharmaceutical and diagnostics companies in Europe and the U.S.
Throughout his career, Andrin has also served on several boards, including the Novartis Foundation for Sustainable Development in Basel, Switzerland; the Global Health Innovation Technology Fund in Tokyo, Japan; and the Global Health Investment Corporation, where he was also a founding member.
Prof. Peter Bauer, MD
Chief Genomic Officer
Peter serves as CGO, combining clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific developments, based on his extraordinary experience, especially in high-throughput genetic testing ...
... using next-generation sequencing.
Peter is passionate about turning medical questions into a complete and fast analytical process, ensuring that the medically driven result is brought back to the clinician and the patient immediately.
After studying Medicine in Freiburg and Berlin, Peter worked as a resident in Neurology at Rostock, and as a resident in Human Genetics at Tübingen since 1997. He received his board certification in Human Genetics in 2006, and heads the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. His experience ranges from medium- to high-throughput genetic analyses, including the application of next-generation sequencing in a clinical setting, genetic research in neurodegenerative disease and hereditary cancer. Peter has an extensive track record in medical and scientific publications, focusing on neurogenetics, oncogenetics, cardiogenetics, and sequencing technology. He is co-principal investigator in a large European consortium on rare neurodegenerative diseases, where he overlooks specifically gene panel, exome and genome sequencing (www.rd-neuromics.eu). Moreover, Peter is vice president of the German Society of Neurogenetics (DGNG).
Chief Financial Officer
Richard serves as CFO, providing international expertise in global financial topics at CENTOGENE. His experience and know-how supports CENTOGENE in its continued global growth plans. With over 25 years of experience in international leadership roles covering ...
... the full width of governance and risk concepts, his expertise, combined with his extensive change management skills, ensures the finance organization will enable the company to continue its expansive growth path.
Richard previously served as Head of Internal Audit at Holcim, a listed multinational company in Switzerland, where he was asked to lead the change of this function from a globally distributed model to a centralized, risk based, model.
From 1985 to 2013 he was active in different Audit- and Management-positions at (a.o.) KPMG, in Chicago, Frankfurt, Hong Kong and the Netherlands. During his international audit tenure, Richard was responsible for audits of a multitude of small and large (listed on various stock exchanges, including the US) clients in a wide variety of industries, including the Pharma industry. He developed a new entity on strategic alliances, where he also provided strategy consulting services, including business planning and related funding. As Partner in Charge of one of the offices, he created values-based turn-around. Subsequently, he was HR responsible in the management team for the audit practice of KPMG NL-south. This role led to a further roll out of his management development initiatives in Hong Kong, China and Germany. Furthermore, Richard was involved in IPO`s and Bond issuances on a variety of stock exchanges. He was an active public speaker during his leadership and business development regarding the role of the China Practice, both in Hong Kong-China, and in Europe – where he led the EMA China Practice.
Richard graduated as a Dutch CPA with the NBA and Tilburg University - the Netherlands, with further executive education programs at Harvard Business School, Insead (Executive MBA), IMD and IESE.
Volkmar Weckesser, PhD
Chief Information Officer
Volkmar serves as CIO, bringing with him broad experience in planning and implementing enterprise information systems, to support both distributed and centralized business operations. His vast skill and know-how supports CENTOGENE in ...
... the global development of IT-based genetic software infrastructure and the mutation data base, CentoMD®.
With over 20 years of experience in IT, management of large transformation programs, and process optimization, he ensures that IT is a key driver for the further development of CENTOGENE.
Volkmar previously served as CIO of the Gothaer Insurance Enterprise and CEO of the incorporated Gothaer Systems GmbH, where he successfully implemented a new IT-strategy, realigned their IT-architecture, and restructured the project portfolio.
From 2009 to 2013 Volkmar was Director IT at DekaBank, guiding the modernization of the IT-systems and the establishment of new IT governance in close collaboration with all parties involved.
Prior to that, he served as Director of IT/Organization at the HSH Nordbank AG. There he focused on planning and implementation of the enterprise-wide IT-strategy. He also successfully realized the consolidation of the IT systems (post-merger IT integration) at the HSH Nordbank AG.
Volkmar started his career as a management consultant for the Mitchell Madison Group and Monitor Company.
He studied techno mathematics at the University of Karlsruhe and holds a PhD in mathematics.
Sun Kim, PhD
Chief Strategy & IR Officer
Sun serves as Chief Strategy & IR Officer with more than two decades of experience in the global pharmaceutical and biotechnology sectors, Sun will have the overall responsibility of working closely with CENTOGENE’s Executive Leadership...
... Team and the Supervisory Board to provide strategic guidance and alignment across the organization, developing scenarios and recommendations to support the Company’s short- and longer- term goals, and communicating company vision with the investment community.
Sun joins CENTOGENE from Shire Pharmaceutical, where he was Head of Corporate Strategy and also responsible for the investor relations function in the USA. Prior to Shire, he worked at Novartis for 6 years in multiple roles including Head of Strategy for Alcon Division and General Manager in Singapore. Sun also worked at Bausch & Lomb heading up its strategy function for the pharmaceutical business unit. Prior to his experience in the pharmaceutical industry, Sun spent 7 years as a Management Consultant at McKinsey & Company and A.T. Kearney.
Sun holds a PhD and MS in chemical engineering from Stanford University, and BS from Seoul National University. Sun is based in CENTOGENE’s Cambridge office.
Philip Lambert, PhD
Chief Scientific Officer
With over two decades of scientific and operational experience in the drug discovery field, Philip has the overall responsibility of driving CENTOGENE’s scientific programs to align with the needs of pharmaceutical partners. Philip joins CENTOGENE from Life Biosciences, a ...
... global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He served as Senior Vice President of Discovery and Labs as well as Chief Operating Officer of two subsidiary companies, Selphagy Therapeutics and Spotlight Biosciences. Prior to Life Biosciences, Philip served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. Philip also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. Moreover, Philip brings vast experience and know-how regarding scientific publications, having contributed to more than thirty publications in peer-reviewed scientific journals.
Philip holds a PhD in Neuropharmacology from Imperial College - University of London and a BSc in Pharmacology from the University of Liverpool. Philip is based in CENTOGENE’s Cambridge office.
Florian Vogel, PhD
Chief Process Officer
Dr. Florian Vogel currently serves as the Chief Process Officer at CENTOGENE GmbH. He has extensive experience in product development and streamlining of workflows for genetically based methods enabling the highest quality as well as high throughput testing. ...
... Florian has more than 10 years of know-how in molecular genetic assay design and international leadership in various industry sections.
Within his current role, he holds disciplinary and budget responsibility for all five Diagnostic wet lab production departments in Rostock, Germany and the CLIA & CAP lab processing facility in Cambridge, Massachusetts. In addition, he is responsible for the Method & Process Development in Rostock. Before taking on this position, he served as Senior Director Research & Development from 2015-2018 at CENTOGENE. Leading up to this, he implemented a genetic quality control division for the biotech company, Euroferm GmbH, and built up a biosafety level 2 group for vaccine vector production. Prior to that, he was living in South Korea to set up a local German branch university and labs for chemical- and bioengineering as Head of White Biotechnology department including lab build out and starting industry collaborations.
Florian studied Biology at Friedrich-Alexander-University of Erlangen-Nurnberg and received his doctoral degree in Molecular Biology with summa cum laude.